Used as a key chiral intermediate in the synthesis of pharmaceutical agents, particularly in the development of kinase inhibitors for targeted cancer therapies. Its structural features enable strong binding to specific enzyme active sites, enhancing selectivity and reducing off-target effects. Commonly employed in the preparation of investigational oncology drugs due to its metabolic stability and favorable pharmacokinetic profile. Also utilized in the design of central nervous system agents where the trifluoromethylpyridine moiety contributes to blood-brain barrier penetration.